Despite initial caution, Carvykti's sales surged, reaching $334M in Q4 2024, driving Legend Biotech Corporation to net income and solidifying its market position. Legend's financial health is ...

In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of ...

The company’s flagship product, Carvykti, a CAR-T therapy for multiple myeloma, has demonstrated strong efficacy and is driving the company’s growth prospects. This comprehensive analysis examines ...

Reports Q4 revenue $186.5M, consensus $179M. “We are coming off a tremendously successful year. Our 2024 total revenue nearly achieved ...

On track to meet their long-stated capacity goal for multiple myeloma therapy Carvykti in 2025, Johnson & Johnson and Legend Biotech are already planning the next phase of their cell therapy ...

We use Adjusted Net Loss and Adjusted Net Loss per Share (which we sometimes refer to as “ANI per Share”) as performance metrics. Adjusted Net Loss and ANI per Share are not defined under IFRS ...

Morgan Stanley analyst Vikram Purohit lowered the firm’s price target on Legend Biotech (LEGN) to $80 from $82 and keeps an Overweight rating ...

Legend Biotech Corp (NASDAQ:LEGN) reported a 110% year-over-year increase in net trade sales of CARVYKTI, reaching approximately $334 million in the fourth quarter of 2024. CARVYKTI has ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Legend Biotech’s financial performance has been strong, with Carvykti sales showing significant growth. According to InvestingPro analysis, the company maintains a healthy financial position ...